<DOC>
	<DOC>NCT00643851</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any pharmacological treatment for diabetes, when compared to initial treatment with monotherapy dapagliflozin or metformin XR. The safety of this treatment will also be studied</brief_summary>
	<brief_title>An Efficacy &amp; Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Males &amp; females, 1877 years old inclusive, with type 2 diabetes and with inadequate glycemic control Drug naive or treated with antidiabetic medication for &lt; 24 weeks since original diagnosis Cpeptide ≥ 1.0 ng/mL Body Mass Index ≤ 45.0 kg/m Serum creatinine &lt; 1.50 mg/dL for men or &lt; 1.40 mg/dL for women AST and/or ALT &gt;3.0 times the upper limit of normal (ULN) Serum total bilirubin &gt; 2.0 mg/dL Creatine kinase &gt; 3X the upper limit of normal (ULN) Symptoms of severely uncontrolled diabetes Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric or rheumatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>